



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكرو فيلم

# بسم الله الرحمن الرحيم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكرو فيلم



# شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



### يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**MONA MAGHRABY**



Fibroscan as Non Invasive Modality for Studying  
the Effect of Hepatic Steatosis on Viral Response  
to Direct – Acting Antiviral in Patients with  
Chronic Hepatitis C

Thesis

Submitted for Partial Fulfillment of Master Degree  
in **Hepatology and Gastroenterology**

By

*Abdallah Abd El Hameed Abd El Mageed Ghoneim*  
*M.B.B.C.h*

Under Supervision of

**Prof. Dr. Amal Shawky Bakir**

*Professor of Internal Medicine and Gastro-enterology*  
*Faculty of Medicine – Ain Shams University*

**Dr. Sarah Abd El Kader Elnakeep**

*Assistant Professor of Internal Medicine and Gastro-  
enterology*  
*Faculty of Medicine – Ain Shams University*

**Dr. Heba Ahmed Faheem**

*Lecturer of Internal Medicine and Gastro-enterology*  
*Faculty of Medicine – Ain Shams University*

Faculty of Medicine - Ain Shams University  
2021



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to Prof. Dr. Amal Shawky Bakeer, Professor of Internal Medicine and Gastro-enterology, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to Dr. Sarah Abd El Kader Elnakeep, Assistant Professor of Internal Medicine and Gastro-enterology, Faculty of Medicine, Ain Shams University, for her sincere efforts, fruitful encouragement.*

*I am deeply thankful to Dr. Heba Ahmed Faheem, Lecturer of Internal Medicine and Gastro-enterology, Faculty of Medicine, Ain Shams University, for her great help, outstanding support, active participation and guidance.*

*I would like to express my hearty thanks to all my family for their support till this work was completed.*

**Abdallah Abd El Hameed Ghoneim**

# List of Contents

Title	Page No.
List of Tables.....	5
List of Figures .....	7
List of Abbreviations.....	9
Introduction .....	- 1 -
Aim of the Work .....	4
Review of Literature	
▪ Hepatitis C Virus.....	5
▪ Direct Acting Antiviral Drugs (DAAs).....	20
▪ Non-Alcoholic Fatty Liver Disease (NAFLD).....	42
▪ Transient Elastography .....	55
Patients and Methods.....	62
Results.....	74
Discussion .....	92
Summary .....	98
Conclusion .....	101
Recommendations .....	102
References .....	103
Arabic Summary	

# List of Tables

Table No.	Title	Page No.
<b>Table 1:</b>	Extra-hepatic manifestations of HCV .....	16
<b>Table 2:</b>	Treatment Regimens HCV according to AASLD, (2017).....	28
<b>Table 3:</b>	Treatment Regimens HCV according to EASL (2018).....	33
<b>Table 4:</b>	TE measurements for steatosis .....	61
<b>Table 5:</b>	Cutoff values for different stages of fibrosis .....	66
<b>Table 6:</b>	Child- Pugh Scoring .....	67
<b>Table 7:</b>	Interpretation.....	68
<b>Table 8:</b>	Characteristics of studied subjects with regard to age and BMI .....	75
<b>Table 9:</b>	Characteristics of studied subjects with regard to gender .....	75
<b>Table 10:</b>	Characteristics of studied subjects with regard to lipid profile.....	76
<b>Table 11:</b>	Characteristics of studied subjects with regard to blood glucose.....	76
<b>Table 12:</b>	Characteristics of studied subjects with regard to non invasive assessment scores.....	77
<b>Table 13:</b>	Characteristics of studied subjects with regard to baseline fibrosis grades as assessed by fibroscan.....	77
<b>Table 14:</b>	Characteristics of studied subjects with regard to fibrosis mean value .....	78
<b>Table 15:</b>	Characteristics of studied subjects with regard to baseline steatosis grade as assessed by fibroscan.....	78
<b>Table 16:</b>	Characteristics of studied subjects with regard to steatosis mean value .....	79
<b>Table 17:</b>	Comparison between patients before and 12weeks after treatment with regard to CBC.....	79



# List of Tables cont...

Table No.	Title	Page No.
<b>Table 18:</b>	Comparison between patients before and 12 weeks post treatment with regard to liver profile .....	81
<b>Table 19:</b>	Characteristics of studied subjects with regard to achievement of sustained virologic response (SVR) after 12 weeks of DAA treatment as defined by Quantitative RNA measured via PCR. ....	85
<b>Table 20:</b>	Characteristics of studied subjects with regard to HCV RNA as quantified by PCR pre-treatment and 12 weeks after the end of treatment to define SVR 12 .....	86
<b>Table 21:</b>	Comparison between SVR & Non-SVR patients with regard baseline parameters .....	88
<b>Table 22:</b>	Comparison between SVR and non SVR as regard response to DAA in different fibrosis stages .....	89
<b>Table 23:</b>	Comparison between SVR and non SVR as regard fibrosis values .....	90
<b>Table 24:</b>	Comparison between SVR and non SVR as regard response to DAA in different steatosis stages .....	91

# List of Figures

Fig. No.	Title	Page No.
<b>Figure 1:</b>	HCV sources of transmission of infection by United States .....	7
<b>Figure 2:</b>	Therapeutic targets of the HCV replication cycle .....	23
<b>Figure 3:</b>	Prevalence of NAFLD in different regions .....	43
<b>Figure 4:</b>	The Spectrum of NAFLD .....	43
<b>Figure 5:</b>	Multiple hit hypothesis for the development of NAFLD .....	46
<b>Figure 6:</b>	The natural history of NAFLD .....	48
<b>Figure 7:</b>	The myriad of CVD risk factors in patients with NAFLD .....	49
<b>Figure 8:</b>	The screen of FibroScan device (EchoSens, Paris, France), last version .....	55
<b>Figure 9:</b>	The area of stiffness that measured by FibroScan .....	56
<b>Figure 10:</b>	Method for measuring liver stiffness using transient elastography .....	57
<b>Figure 11:</b>	TE measurements for fibrosis .....	60
<b>Figure 12:</b>	Hemoglobin level 12 weeks post treatment among studied groups significantly decreased .....	80
<b>Figure 13:</b>	Hemoglobin level 12 weeks post treatment among studied groups significantly decreased .....	80
<b>Figure 14:</b>	AST among studied groups decreased 12 weeks post treatment. ....	82
<b>Figure 15:</b>	AST among studied groups decreased 12 weeks post treatment. ....	82
<b>Figure 16:</b>	ALT among studied groups decreased 12 weeks post treatment. ....	83
<b>Figure 17:</b>	ALT among studied groups decreased 12 weeks post treatment. ....	83

# List of Figures cont...

Fig. No.	Title	Page No.
<b>Figure 18:</b>	Albumin among studied groups decreased 12 weeks post treatment. ....	84
<b>Figure 19:</b>	Albumin among studied groups decreased 12 weeks post treatment. ....	84
<b>Figure 20:</b>	Characteristics of studied subjects with regard to HCV RNA as Quantified by PCR, pre –treatment and 12 weeks after the end of treatment to define SVR 12.....	87
<b>Figure 21:</b>	Characteristics of studied subjects with regard to HCV RNA as Quantified by PCR, pre –treatment and 12 weeks after the end of treatment to define SVR 12.....	87
<b>Figure 22:</b>	Correlation between Fibrosis stages and Response to DAA .....	89
<b>Figure 23:</b>	Impact of hepatic fibrosis on SVR-12.....	90
<b>Figure 24:</b>	Correlation between Steatosis stages and Response to DAA. ....	91

# List of Abbreviations

Abb.	Full term
<i>AFP</i>	<i>Serum alpha-fetoprotein</i>
<i>ALT</i>	<i>Alanine aminotransferase</i>
<i>AST</i>	<i>Aspartate transaminase</i>
<i>CAP</i>	<i>Controlled attenuation parameter</i>
<i>CBC</i>	<i>Complete blood count</i>
<i>COX-2</i>	<i>Cyclooxygenase-2</i>
<i>DAA</i>	<i>Direct Antiviral Agents</i>
<i>DAAs</i>	<i>Direct Acting Antiviral Drugs</i>
<i>EHMs</i>	<i>Extra-hepatic manifestations</i>
<i>EIA</i>	<i>Enzyme immunoassay</i>
<i>ELISA</i>	<i>Enzyme-Linked Immunosorbent Assay</i>
<i>FBS</i>	<i>Fasting blood sugar level</i>
<i>FFA</i>	<i>Free fatty acids</i>
<i>FLI</i>	<i>Fatty liver index</i>
<i>GGT</i>	<i>Gamma glutamyl transferase</i>
<i>HCC</i>	<i>Malignancy either primary</i>
<i>HCV</i>	<i>Hepatitis C virus</i>
<i>HDL</i>	<i>High density lipo-protien</i>
<i>HSCs</i>	<i>Hepatic stellate cells</i>
<i>HVR</i>	<i>Hyper variable regions</i>
<i>IDU</i>	<i>Intravenous drug use</i>
<i>IgG</i>	<i>Immunoglobulin G</i>
<i>INR</i>	<i>International normalized ratio</i>
<i>IQR</i>	<i>Interquartile range interval</i>
<i>ISGs</i>	<i>INF-stimulated genes</i>
<i>KCs</i>	<i>Kuppfer cells</i>
<i>kPa</i>	<i>kiloppascals</i>
<i>LDL</i>	<i>Low density lipo-protein</i>
<i>LSM</i>	<i>Liver stiffness measurement</i>
<i>LTx</i>	<i>Liver transplantation</i>
<i>MIP1<math>\alpha</math>-1<math>\beta</math></i>	<i>Macrophages inflammatory proteins</i>
<i>NAFLD</i>	<i>Non-alcoholic fatty liver disease</i>
<i>NASH</i>	<i>Non-alcoholic steatohepatitis</i>

# List of Abbreviations cont...

Abb.	Full term
<i>NIs</i>	<i>Nucleotide inhibitors</i>
<i>NNIs</i>	<i>Non-nucleotide inhibitors</i>
<i>NS</i>	<i>Nonstructural</i>
<i>NS</i>	<i>Non Structural</i>
<i>PCR</i>	<i>Polymerase Chain Reaction</i>
<i>PDFF</i>	<i>Proton density fat fraction</i>
<i>R155K</i>	<i>Retains activity against mutated Arg155</i>
<i>RIG-1</i>	<i>Retinoic acid-inducible gene 1</i>
<i>SR</i>	<i>Success rate</i>
<i>SVR</i>	<i>Sustained virologic response</i>
<i>TE</i>	<i>Transient elastography</i>
<i>TLRs</i>	<i>Toll-like receptors</i>
<i>VCTE</i>	<i>Vibration controlled transient elastography</i>

## ABSTRACT

**Background:** Hepatic steatosis in hepatitis C virus (HCV) infected patients has been shown to enhance the progression of liver fibrosis and cirrhosis. Liver biopsy was the gold standard for diagnosis of hepatic steatosis. However, liver biopsy is an invasive procedure and associated with complication (e.g., bleeding). Recently, controlled attenuation parameter (CAP) in transient elastography (TE) has been introduced to detect and quantify hepatic steatosis. CAP measures the ultrasonic attenuation in the liver tissue depending on the viscosity [fat] of the medium [liver] and the distance of propagation of the ultrasonic signals into the liver. Non alcoholic fatty liver disease (NAFLD) was defined by CAP values  $\geq 216$  dB/m. Direct-acting antiviral (DAA) therapy is associated with high sustained virologic response (SVR) and overcomes negative predictive factors including steatosis.

**Objectives:** The aim of this study to use the fibroscan as non invasive modality for study the impact of hepatic steatosis on SVR in HCV infected patients receiving DAA therapy.

**Results:** This study was conducted on 40 patients diagnosed as HCV with NAFLD based on positive anti-HCV antibody, positive HCV viremia, abdominal ultrasonography, serum liver enzymes, body mass index (BMI). All patients assessed by TE with CAP to detect and quantify hepatic steatosis (CAP cut off value  $\geq 216$  dB/m) and also assessed by non invasive scores (APRI score, FIB-4 score, HSI score). After start of antiviral treatment, patients were seen every 4 weeks until the end of therapy and 12 weeks after the end of therapy to assess SVR-12. The overall SVR-12 (n=36) was 90% and was not impacted by presence of hepatic steatosis.

**Conclusion:** Our study confirmed that hepatic steatosis has no impact on SVR in HCV infected patients receiving DAA therapy. TE with CAP can be used as non invasive method for assessment of hepatic steatosis.

**KEYWORDS:** FIBROSCAN, NON INVASIVE MODALITY, HEPATIC STEATOSIS, VIRAL RESPONSE TO DIRECT, ACTING ANTIVIRAL, CHRONIC HEPATITIS C



## INTRODUCTION

**H**epatitis C virus (HCV) infection is a major cause of chronic liver disease, more than 185 million people are infected in the whole world (*Gower et al., 2016*). Egypt has the highest world wide prevalence (8%-12%) country wide and up to 50% in age above 50 years in certain rural areas due to specific modes of infection (*Elghraably et al., 2017*). The long term impact of HCV infection is highly variable, ranging from minimal effects to chronic hepatitis advanced fibrosis, cirrhosis, decompensated cirrhosis and hepatocellular carcinoma. Chronic HCV infection may also induce severe extra-hepatic complications (*Maasoumy and Wedemeyer, 2016*).

The primary goal of HCV therapy is to cure the infection, i.e. to achieve a sustained virological response (SVR) which defined as undetectable HCV RNA 12 weeks (SVR12) or 24 weeks (SVR24) after treatment completion. Long-term follow up studies have shown that an SVR corresponds to a definitive cure of the HCV infection, with a very low chance of late relapse (*Bruno et al., 2016*).

Direct Antiviral Agents (DAA) can be divided into 3 classes defined by the Non Structural (NS) HCV protein they target: NS3 Protease inhibitors, NS5B Polymerase inhibitors and NS5A protein inhibitors (*Swain et al., 2015*). The high efficacy, combined with the near perfect safety profile of DAAs, has challenged the need for regular on treatment